Foresite Capital Management IV, LLC

Filings by Foresite Capital Management IV, LLC span 3 companies, the busiest being Eikon Therapeutics, Inc., Kinnate Biopharma Inc. and Aerie Pharmaceuticals Inc. Over a trading history stretching from 7 November 2019 to 4 February 2026, the count stands at 33 filings.

The open-market record is one-sided, with 3 purchases worth €5.4M and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 9 share grants. 2026 to date brings 1 purchase and no sales.

A typical purchase (the median) is worth €846k. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 6 February 2026, the filings show a transaction in Eikon Therapeutics, Inc. The last purchase on record was published on 6 February 2026, which is 259 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.